Gallant Pet

Gallant Pet, Inc., which also trades under the name Gallant Therapeutics, is a San Diego-based veterinary biotechnology company founded in 2018 that develops regenerative medicine, specifically stem cell therapies, for dogs and cats. Its approach centers on an off-the-shelf (ready-to-use) stem cell platform intended to address the underlying causes of disease rather than only manage symptoms, with stated mechanisms of reducing inflammation, restoring tissue function and supporting long-term recovery. The company isolates and expands mesenchymal stem cells (MSCs) from qualified donors; per company materials, MSCs modulate immune responses by engaging T-cells, B-cells, NK cells and dendritic cells through direct contact or secreted immunomodulatory factors, and can differentiate into bone, cartilage, muscle and adipose cells.

Gallant's pipeline spans feline chronic gingivostomatitis, feline osteoarthritis, canine osteoarthritis, feline chronic kidney disease and canine atopic dermatitis, with programs tracked across pre-clinical proof of concept, controlled field study, pivotal study and commercial availability stages under the FDA's structured review and approval process. The company runs multi-state clinical trials with veterinary clinics across the United States and recruits pet owners into enrolling studies. It also operates GallantU, a free RACE-approved continuing education program for veterinary professionals offering on-demand courses and live webinars, alongside a science library and educational content for veterinarians and pet owners.

Earlier in its history the business was oriented toward consumer stem cell banking for pets, selling collection kits to pet owners for cells harvested by veterinarians from reproductive tissue normally discarded during spay or neuter procedures. That direct-to-consumer offering is no longer sold; pet owners now engage with the company primarily through participation in open clinical trials.

Founding story

Aaron Hirschhorn founded Gallant after his own chronic back pain was treated with stem cell therapy at the same time his dog was suffering from severe arthritis severe enough to impair walking. Seeking to determine whether a similar approach could help his dog, he developed the service with veterinary scientists and investors, building it around collecting stem cells from reproductive organs typically discarded during spay or neuter procedures in young animals.

Business model

Gallant develops veterinary biologics intended for administration by veterinarians in everyday clinical practice, describing its investigational therapies as ready-to-use and easy to administer. Therapies are advanced through FDA review stages toward commercial availability, and the company engages veterinary clinics as clinical trial partners and as the channel for eventual delivery. It previously operated a subscription-priced consumer stem cell banking kit (about $95 per year, ordered by the pet owner and taken to a veterinarian) alongside stem cell collection, banking and regenerative treatment services, but no longer sells directly to consumers.

Traction

Gallant reports positive pilot data for its feline osteoarthritis and IV-delivered canine osteoarthritis stem cell programs and eligibility for the FDA's expanded conditional approval pathway for both. It completed a phase one proof-of-concept trial in canine atopic dermatitis, a condition it says affects as many as 13 million dogs, and planned a phase two placebo-controlled trial in 2025. As of early 2025 it had trials underway for feline chronic gingivostomatitis in eight states, feline chronic kidney disease in nine states, canine osteoarthritis in eight states and feline osteoarthritis in eight states, and it has published white papers and conducted a national survey of veterinary professionals on stem cell therapy.

Latest developments

Gallant announced progress on its IV-delivered canine osteoarthritis stem cell therapy with pilot data and expanded eligibility for the FDA conditional approval pathway, and reported positive pilot data plus FDA expanded conditional approval pathway eligibility for its feline osteoarthritis therapy. It also released results of a national survey in which veterinary professionals characterized stem cell therapy as a new tool for inflammatory diseases in pets. In June 2025 the company raised $18 million in Series B funding led by returning investor Digitalis Ventures, earmarked for product development, with accompanying manufacturing expansion reported by BioProcess Insider.